Evolus reports record Q4 2024 revenue $79.0M (+30% YoY); achieves full-year profitability ahead of expectations

Evolus, Inc.

Record Q4 revenue $79.0M (+30% YoY); full-year $266.3M (+32% YoY).
GAAP op loss improved to $2.3M Q4; non-GAAP op income $6.7M Q4 and $0.3M full year (profitability ahead of schedule).
Evolysse FDA approval Feb 2025; launch Q2 2025; expected 8-10% of 2025 revenue.
2025 revenue guidance $345-355M (30-33% growth); expects positive non-GAAP op income for full year.
Added ~2,900 new accounts in 2024; total >15,300 accounts; over 50% US account penetration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.